Bryan, Garnier & Co downgraded shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) from a buy rating to a neutral rating in a research report released on Thursday morning, MarketBeat Ratings reports. A number of other equities research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an overweight rating and issued a $65.00 […]
Cantor Fitzgerald restated their overweight rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $65.00 price objective on the stock. Other equities research analysts have also recently issued reports about the stock. Barclays raised their target price on shares […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) had its price target raised by Barclays from $41.00 to $59.00 in a research report sent to investors on Tuesday, Marketbeat reports. Barclays currently has an equal weight rating on the stock. A number of other brokerages have also recently issued reports on MLTX. Wedbush restated an outperform rating […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) had its target price lifted by research analysts at Barclays from $41.00 to $59.00 in a research report issued on Tuesday, Marketbeat.com reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 2.36% from the company’s previous […]
Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The […]